Discussion topic:
The power and limitations of immunobridging studies: the example of COVID-19 vaccines
Chair: Hanna Nohynek,
Finnish Institute for Health and Welfare, Finland and Member of the ADVAC Scientific Committee
Presentations :

Bridging studies – why and how?
Peter Dull, Bill & Melinda Gates Foundation

Criteria and requirement for the licensing of new vaccines with special emphasis on COVID-19
the view of EMA. Marco Cavaleri, Head of Office Biological Health Threats and Vaccine Strategy, European Medicines Agency.

Panel discussion:  Strategies behind the variant adapted COVID-19 vaccines development
with participation from regulators, Godwin Enwere, WHO Prequalification Unit, Vikram Paradkar, Executive Vice-President   Production, Biological E, representing DCVMN, Jeff Roberts, Associate Vice-President Clinical Research, MSD, representing   IFPMA, and other experts.